

In the Claims

Claim 1 (Currently amended): A method of increasing the number of hematopoietic stem cells in peripheral blood of a patient, comprising administering an effective amount of an RNA interference molecule targeting SH2-domain containing inositol 5-phosphatase (SHIP) to the patient, wherein the number of hematopoietic stem cells in the peripheral blood of the patient are thereby increased.

Claims 2-17 (Cancelled)

Claim 18 (Currently amended): The method of claim 1, further comprising harvesting the hematopoietic stem cells from the patient after said administering.

Claim 19 (Previously presented): The method of claim 18, wherein said harvesting comprises leukopheresis.

Claim 20 (Currently amended): The method of claim 18, further comprising administering the harvested hematopoietic stem cells to the patient.

Claim 21 (Cancelled)

Claim 22 (Previously presented): The method of claim 1, wherein the RNA interference molecule is administered intravenously.

Claim 23 (Cancelled)

Claim 24 (Currently amended): The method of claim 1, wherein said administering mobilizes the hematopoietic stem cells to the peripheral blood.

Claim 25 (Previously presented): The method of claim 1, wherein the patient has undergone myeloablation.

Claims 26 - 32 (Cancelled)

Claim 33 (Previously presented): The method of claim 1, wherein the RNA interference molecule is administered to the patient for 1 week or 2 weeks.

Claim 34 (Cancelled)